| Document |
Document Title |
|
WO/2021/066639A1 |
The present invention provides a tryptophan derivative used in agrochemistry, which has a preventive and corrective antiviral effect against begomovirus in plants, does not display phytotoxicity in field concentrations and is not toxic t...
|
|
WO/2021/047978A1 |
The present invention relates to a process for the preparation of α-methyl-[4-(nitro)-2- (trifluoromethyl)]-benzyl nitrate and to the α-methyl-[4-(nitro)-2-(trifluoromethyl)]-benzyl nitrate.
|
|
WO/2021/042411A1 |
Disclosed are an AKR1C3 inhibitor or a pharmaceutically acceptable salt of same, a preparation method for same, and uses thereof. A structural optimization is performed with a nonsteroidal anti-inflammatory medicament, flurbiprofen, serv...
|
|
WO/2021/045207A1 |
The present invention relates to a production method for a highly reactive intermediate. The production method includes: preparing an electron-accepting active compound (1); preparing a piezoelectric material (3); and applying mechanical...
|
|
WO/2021/031431A1 |
Disclosure relates to a use of a fluorination gas, wherein the elemental fluorine is present in a high concentration, for example, in a concentration of elemental fluorine, especially of equal to much higher than 15 % or even 20% by volu...
|
|
WO/2021/019998A1 |
Provided is a compound capable of realizing a lubricant having excellent adhesion to a magnetic disc, especially to a protective layer. A perfluoropolyether compound according to an embodiment of the present invention has a structure in ...
|
|
WO/2021/012689A1 |
Disclosed herein are phenylthiophene sulfonamide compounds, pharmaceutical compositions, a preparation method therefor and use thereof. The compounds of the present invention are capable of effectively and selectively inhibiting Bcl-xL, ...
|
|
WO/2021/000862A1 |
The present invention provides an AKR1C3 inhibitor of compounds of the following formulas and pharmaceutically acceptable salts or solvates or isotopically substituted compounds thereof and medical use.
|
|
WO/2021/001044A1 |
Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of Eltrombopag, passing through/using intermediate 5'-Chloro-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid alkaline metal sal...
|
|
WO/2020/248127A1 |
A borohydride reduction stabilizing system and a method for reducing an ester to an alcohol. The borohydride reduction stabilizing system comprises: a borohydride reducing agent and a stabilizing agent for stabilizing the borohydride red...
|
|
WO/2020/248279A1 |
The present invention provides a continuous synthesis method for a substituted benzoate organic matter. The continuous synthesis method comprises: in the presence of a catalyst and an organic solvent, continuously feeding an organic matt...
|
|
WO/2020/248278A1 |
The present invention provides a method for the continuous synthesis of a substituted benzoic-acid organic substance. The continuous synthesis method comprises: in the presence of catalyst and organic solvent, the organic matter represen...
|
|
WO/2020/247927A1 |
The current inventive technology includes systems, methods, and compositions for directly synthesizing sticky ended DNA fragments for subsequent gene assembly. In a preferred embodiment, the inventive technology includes strategies for t...
|
|
WO/2020/238862A1 |
The present invention provides a fluorene initiator, a photocurable composition comprising same, and an application thereof. The fluorene photoinitiator has a structure represented by formula (I) or formula (II). In the photoinitiator, o...
|
|
WO/2020/230555A1 |
A method for forming a carbon-carbon bond, wherein: a reaction is performed by filling a container with a platinum group metal-loaded catalyst and having a starting material liquid permeate through the platinum group metal-loaded catalys...
|
|
WO/2020/210175A1 |
The present invention provides a nitroreductase-releasable pro-drug of Formula (I); where Ar1, m, n, Z, Y, L, and A are as defined herein, and methods for using and producing the same. Compound of formula (I) is useful in oral administra...
|
|
WO/2020/192348A1 |
Disclosed are phenyl allylidene cyclohexenone derivatives with the structure shown in general formula I. In combination with structural characteristics and structure-function relationship of piplartine, amino bonds are replaced with doub...
|
|
WO/2020/164217A1 |
Disclosed is a process for the manufacture of fluoroaryl compounds and derivatives thereof, in particular of fluorobenzenes and derivatives thereof, and especially wherein said manufacture relates to an environmentally friendly productio...
|
|
WO/2020/161362A1 |
The disclosure provides a process for the preparation of 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof, contemplated to be capable of modulating the activity of receptors, e.g., PPARs receptors.
|
|
WO/2020/148641A1 |
The present invention relates to a process for preparation of 2-Amino-5-hydroxypropiophenone, a key intermediate for the synthesis of camptothecin analogs including 7-Ethyl-10-hydroxycamptothecin (SN-38).
|
|
WO/2019/195761A3 |
Methods of treating presbyopia or cataract in a subject in need thereof are provided, The methods require administering to the subject an effective amount of a composition comprising a compound that inhibits the formation of high molecul...
|
|
WO/2020/137921A1 |
The present invention provides an actinic light sensitive or radiation sensitive resin composition, a resist film, a pattern forming method, and an electronic device production method, wherein the actinic light sensitive or radiation sen...
|
|
WO/2020/102529A1 |
A method comprising co-administering to a subject having cancer, suspected of having cancer, or at risk of developing cancer: a therapeutically effective amount of at least one compound (a) selected from (a)(i) a nitroalkene fatty acid, ...
|
|
WO/2020/084094A1 |
The present invention relates to a process for preparing a nitrated compound, comprising the step of reacting a compound (A) comprising at least one substituted or unsubstituted aromatic or heteroaromatic ring, wherein said heteroaromati...
|
|
WO/2020/050368A1 |
The purpose of the present invention is to provide: a method for preparing a Vilsmeier reagent, that can be carried out safely, easily, and at a low cost; and a method for producing an aromatic aldehyde or an aromatic ketone, a carboxyli...
|
|
WO/2020/047182A1 |
The present invention relates to compositions of pibrentasvir, drug products thereof, and processes and intermediates for the preparation thereof. This invention relates to the drug product, active drug substance, intermediates, and proc...
|
|
WO/2020/040614A1 |
The present invention provides: a preparation method for a (3R,5R)-7-[2-(4-flurophenyl)-5-isopropyl-3-phenyl-4-[(4-hydr
oxymethylphenylamino)carbonyl]-pyrrrol-1-yl]-3,5-dihydroxy heptanoic acid hemicalcium salt; an intermediate used ther...
|
|
WO/2020/029762A1 |
A preparation method for a fused tricyclic γ-amino acid derivative and an intermediate thereof, and a method for preparing an intermediate of the fused tricyclic γ-amino acid derivative. The fused tricyclic γ-amino acid derivative has...
|
|
WO/2020/028396A1 |
The present invention relates to an analytical method that includes providing a sample potentially containing a chiral analyte that can exist in stereoisomeric forms, and providing a probe selected from the group consisting of coumarin-d...
|
|
WO/2020/011626A1 |
The present invention refers to a crystalline 2-fluoro-3-nitrotoluene compound of formula (I), and a process for the preparation thereof. Furthermore, the present invention relates to a process for the synthesis of a compound of formula ...
|
|
WO/2020/010900A1 |
The present invention provides a use of a compound shown in Formula I/II in a drug for preventing, treating, or alleviating pain.
|
|
WO/2019/242010A1 |
Provided is a compound or a salt thereof as a linking chain. The compound or a salt thereof can be loaded onto a solid-phase resin for solid-phase synthesis of a polypeptide drug, thereby improving the synthetic yield of the polypeptide ...
|
|
WO/2019/230653A1 |
The present invention provides a compound represented by formula (I): [symbols in the formula are as described in the specification].
|
|
WO/2019/191363A3 |
Disclosed herein are improved methods for the preparation of oseltamivir, and intermediates useful thereto.
|
|
WO/2019/199621A4 |
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (I...
|
|
WO/2019/216415A1 |
The present disclosure addresses the problem of providing a production method for a novel fluoromethyl derivative. The problem is solved by a production method that is for a fluorinated organic compound represented by formula (1) [in the...
|
|
WO/2019/213545A1 |
The present disclosure provides processes for the preparation of cerdulatinib, which is of formula (I): Formula (I) or a salt thereof. The disclosure also provides intermediates and processes for the preparation of the intermediates usef...
|
|
WO/2019/199621A1 |
The present invention is directed to bi-functional compounds which find use as pharmaceutical agents in the treatment of disease states and/or conditions which are through.macrophage migration inhibitory factor (MIF) or immunoglubin G (I...
|
|
WO/2019/174974A1 |
The invention relates to a fertilizer composition comprising a) zeolitic imidazolate framework ZIF-8; and b) a fertilizer selected from liquid or solid ammonium-containing inorganic fertilizers, liquid or solid organic fertilizers, and u...
|
|
WO/2019/174977A1 |
The invention relates to a composition comprising a) zeolitic imidazolate framework ZIF-8; and b) Compounds of formula (I) or a stereoisomer, salt, tautomer or N-oxide thereof, wherein the variables have a meaning as defined in the main ...
|
|
WO/2019/172184A1 |
Provided is a metal imide complex which has a stable structure and is able to be easily synthesized, while being capable of efficiently oxidizing various substrates. A metal imide complex which contains a metal and an imide that serves a...
|
|
WO/2019/168269A1 |
The present invention relates to a bifunctional chiral organocatalytic compound having excellent enantioselectivity, a preparation method therefor, and a method for producing a non-natural gamma amino acid from a nitro compound by using ...
|
|
WO/2019/159596A1 |
Provided is a method for preparing a coupled body represented by general formula (3), the coupled body being obtained by reacting a compound represented by general formula (1) and a compound represented by general formula (2) in the pres...
|
|
WO/2019/154728A1 |
The present invention relates to processes for preparation of 1 -nitrobenzene-2- alkyloxycarbonyl-5-carboxylic acid. In particular, the present invention relates to preparation of 1 -nitrobenzene-2-alkyloxycarbonyl-5-carboxylic acid by p...
|
|
WO/2019/130046A1 |
Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.
|
|
WO/2019/108773A1 |
The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFκB and as agonists (activators) of Nrf2. In particular, these compounds show dual activity and makes them par...
|
|
WO/2019/100021A1 |
A construct comprising a dermal extracellular matrix gel, polymer fibers, and microparticles containing a nitro oleic acid agent.
|
|
WO/2019/069961A1 |
Provided is a compound represented by general formula (I-1). (In the formula, A denotes an atomic group having an antioxidant function, B denotes a photo-releasable group, and k denotes an integer between 1 and 10.) Also provided is a co...
|
|
WO/2019/008156A1 |
The present invention provides novel compounds of formula (I) that are useful as inhibitors of the PD-1/PD-L1 protein/protein interaction. The compounds may be used in the treatment of cancer, infectious diseases and neurodegenerative di...
|
|
WO/2018/237344A1 |
Disclosed herein are methods and compounds for treating a cancer is characterized with an elevated expression of thioredoxin reductase (TrxR) or an elevated expression of peroxiredoxin (PRDX). In some embodiments, also disclosed herein a...
|
